STAAR/$STAA
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About STAAR
Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company also makes lenses that are used in surgery to treat cataracts. The company offers two types of products: Implantable Collamer lenses (ICL) and intraocular lens (IOL). The ICLs are used in refractive surgery and IOLs are used in cataract surgery. The majority of its sales are generated from the ophthalmic surgical product segment.
Ticker
$STAA
Sector
Primary listing
Employees
1,157
Headquarters
Website
STAAR Metrics
BasicAdvanced
$1.3B
-
-$1.95
1.02
-
Price and volume
Market cap
$1.3B
Beta
1.02
52-week high
$30.81
52-week low
$13.50
Average daily volume
1.2M
Financial strength
Current ratio
5.211
Quick ratio
4.157
Long term debt to equity
9.555
Total debt to equity
11.057
Profitability
EBITDA (TTM)
-53.993
Gross margin (TTM)
73.87%
Net profit margin (TTM)
-41.79%
Operating margin (TTM)
-27.18%
Effective tax rate (TTM)
-4.81%
Revenue per employee (TTM)
$200,000
Management effectiveness
Return on assets (TTM)
-7.88%
Return on equity (TTM)
-24.65%
Valuation
Price to revenue (TTM)
5.542
Price to book
3.61
Price to tangible book (TTM)
3.91
Price to free cash flow (TTM)
-32.321
Free cash flow yield (TTM)
-3.09%
Free cash flow per share (TTM)
-0.8
Growth
Revenue change (TTM)
-32.42%
Earnings per share change (TTM)
-543.26%
3-year revenue growth (CAGR)
-6.19%
10-year revenue growth (CAGR)
12.23%
3-year earnings per share growth (CAGR)
36.31%
10-year earnings per share growth (CAGR)
24.94%
What the Analysts think about STAAR
Analyst ratings (Buy, Hold, Sell) for STAAR stock.
Bulls say / Bears say
The board approved a $30 million share repurchase program on May 16, 2025, signaling management’s confidence in STAAR’s fundamentals and a continued focus on disciplined capital allocation (Nasdaq).
As of March 28, 2025, STAAR had $222.8 million in cash and investments and no debt, ensuring ample liquidity to support growth plans and weather market volatility (Nasdaq).
The appointment of Deborah Andrews as CFO on June 25, 2025, and the creation of a new Capital Stewardship Committee highlight strengthened financial discipline, with STAAR tracking ahead of plan toward a $225 million SG&A run rate (Business Wire).
Q1 2025 revenues dropped to $42.59 million from $77.36 million a year earlier, highlighting ongoing weak demand and margin pressures in STAAR’s core ICL business (Nasdaq).
For the nine months ended September 26, 2025, Chinese distributors reduced inventory by about $80 million–$85 million, leading to lower year-to-date net sales and exposing difficulties in the critical China market (Nasdaq).
William Blair downgraded STAA to Market Perform due to limited visibility, uncertain demand stimulus in China, and rising competition from LASIK and other refractive solutions, which may hinder STAAR’s growth outlook (Benzinga).
Data summarised monthly by Lightyear AI. Last updated on 6 Nov 2025.
STAAR Financial Performance
Revenues and expenses
STAAR Earnings Performance
Company profitability
STAAR News
AllArticlesVideos
STAAR Surgical Announces Amendments to Alcon Merger Agreement
Business Wire6 days ago
Yunqi Capital Applauds STAAR Surgical's Strong Third Quarter Results and Reiterates That the Proposed Sale to Alcon Should Be Terminated
Business Wire1 week ago
Broadwood Partners Condemns Alcon's Fallacious Attacks on STAAR Surgical and Its Prospects
Business Wire1 week ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for STAAR stock?
STAAR (STAA) has a market cap of $1.3B as of November 13, 2025.
What is the P/E ratio for STAAR stock?
The price to earnings (P/E) ratio for STAAR (STAA) stock is 0 as of November 13, 2025.
Does STAAR stock pay dividends?
No, STAAR (STAA) stock does not pay dividends to its shareholders as of November 13, 2025.
When is the next STAAR dividend payment date?
STAAR (STAA) stock does not pay dividends to its shareholders.
What is the beta indicator for STAAR?
STAAR (STAA) has a beta rating of 1.02. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.